Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Perry B. Hudson"'
Publikováno v:
Urology. 61:573-578
Objectives To investigate whether interstitial laser coagulation (ILC) is as effective and as safe as transurethral resection of the prostate (TURP). The treatment of choice for bladder outflow obstruction secondary to benign prostatic hyperplasia is
Autor:
Johnny Roy, Harold A. Fuselier, John D. McConnell, Reginald Bruskewitz, Gerald Andriole, Gholem H. Malek, Alvin M. Matsumoto, Jaime Bonilla, Lloyd H. Harrison, Patrick C. Walsh, Martin I. Resnick, Joanne Waldstreicher, Sidney Rosenblatt, Paul F. Schellhammer, Perry B. Hudson, Claus G. Roehrborn
Publikováno v:
Journal of Urology. 163:13-20
Purpose: We analyze patterns of prostate growth in men diagnosed with benign prostatic hyperplasia (BPH) and treated with placebo during 4 years, and determine which baseline parameters were the st...
Autor:
Sidney Rosenblatt, Jack Geller, John Trachtenberg, Gholam H. Malek, Michael M. Lieber, Mostafa M. Elhilali, Perinchery Narayan, Elizabeth Stoner, Reginald C. Bruskewitz, Johnny B. Roy, Amy T Ko, Nicholas A. Romas, Carol A. Jacobsen, Perry B. Hudson, Jean-Paul Perreault, Lynn A. Patterson, Richard Norman, Rex Boake
Publikováno v:
Urology. 53:690-695
Objectives. The purpose of this open-label study extension was to assess the long-term safety and efficacy of finasteride in the treatment of men with benign prostatic hyperplasia (BPH). Methods. A Phase III North American BPH trial originally enroll
Autor:
Perry B. Hudson, J. Waldstreicher, H. A. Guess, Gerald L. Andriole, L. Patterson, N. A. Romas, Jonathan I. Epstein, C. L. Jackson, T. J. Cook, E. D. Crawford, D. Kadmon, H. Wise
Publikováno v:
Urology. 52:195-202
Objectives. To evaluate prostate cancer detection and prostate-specific antigen (PSA) among men with benign prostatic hyperplasia treated with finasteride. Methods. Three thousand forty men 45 to 78 years of age with PSA less than 10 ng/mL and no his
Publikováno v:
Diagnostic Molecular Pathology. 7:44-50
The expression of macrophage migration inhibitory factor (MIF) in prostate tissue was investigated by immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), and Northern blot analysis using a prostate tissue bank. MIF expression was e
Autor:
Perry B. Hudson, Michael E. Lombardo
Publikováno v:
Steroids. 62:682-685
The objective of this study was to find a biomarker, easily detectable and measurable, that could be useful to the physician for the diagnosis and management of prostate cancer. An immunoaffinity-purified polyclonal antibody to the 5α-reductase type
Publikováno v:
The Prostate. 29:381-385
BACKGROUND. The increasing incidence of prostate cancer demands that we give our full attention not only to the etiology and prevention of this common type of cancer, but also to the diagnosis and prognostic course of this disease. In an effort to de
Autor:
George P Einstein, R. Keith Bailey, Perry B Hudson, Julio Martinez, David Karam, Orien L Tulp, Bruce H Robinson
Publikováno v:
The FASEB Journal. 26
Autor:
Richard Alt, Perry B. Hudson
Publikováno v:
American journal of surgery. 72
ARCINOMA of the stomach has aIways been a bIack chapter in surgery. Both diagnosis and therapy have been inadequate and reIativeIy ineffective. Enormous achievement in other branches of abdomina1 surgery notwithstanding, the genera1 outIook for a pat
Autor:
Laurie A. Lamonde, Julio M. Pow-Sang, Perry B. Hudson, Melissa Honour, Kathryn M. Kash, Paul B. Jacobsen
Publikováno v:
Psycho-oncology. 13(2)
Men with a positive family history of prostate cancer are known to be at increased risk for the disease; however, relatively little is known about their risk perceptions or screening behavior. To address these issues, the current study examined the r